K-554 / Kallyope - LARVOL DELTA

Kallyope To Present at the 44th Annual J.P. Morgan Healthcare Conference (Businesswire) - "During the presentation, Mr. Galeota will provide an overview of the Company’s lead programs, including elismetrep (K-304), an oral Transient Receptor Potential Melastatin 8 (TRPM8) antagonist for the acute treatment of migraine, expected to begin pivotal studies in mid-2026, and K-554, which targets a non-incretin peptide receptor for weight loss and glucose control and will enter Phase 1 clinical studies in mid-2026."

New trial • Diabetes • Migraine • Obesity